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Abstract 
The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 
(PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein 
thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following 
orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone 
orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis 
progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the 
plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched controls. We also 
studied PAI-1 activity in plasma. The presence of 4G/5G genotype was significantly increased in the group of 
patients with the extension of thrombotic lesions and was associated with an increase in CVT extension risk 
(odds ratio adjusted for sex 2.692; 95% confidence interval 1.302-4.702). Moreover, we observed a 
significant increase of PAI-1 plasma activity in patients with extension of thrombotic lesion vs. patients 
without extension (P=0.0001). Patients with 4G/5G genotype in the promoter of the plasminogen activator 
inhibitor - 1 gene present a higher risk of extension of thrombotic lesions. 
 
